BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Jun 12, 2021
Finance

Right or wrong, the aducanumab decision could turbo-boost investor interest in neurodegeneration

If accelerated approval based on surrogate endpoints becomes a reality, risk takes on a new profile
BioCentury | Sep 22, 2017
Company News

Management tracks: Unity, Shield, Tusk

BioCentury | Aug 11, 2017
Strategy

The flip-side of immunotherapy

How immuno-oncology targets are spawning new therapies for inflammation
BioCentury | May 25, 2017
Clinical News

Aprea starts Phase Ib/II of APR-246 for MDS

BioCentury | Apr 27, 2017
Clinical News

IMP321: Ph I TACTI-mel ongoing

Items per page:
1 - 10 of 106